Wang is set to contribute to a session titled Competing in a New Global Playing Field, sharing the stage with prominent industry figures including Mass General Brigham CEO Anne Klibanski, Incyte CEO Bill Meury, and Nobel laureate Phil Sharp. The forum facilitates private dialogues among leaders from government, academia, and the investment sector to address systemic challenges in drug development.

Phanes Therapeutics currently maintains an active clinical pipeline with three Phase 2 trials under evaluation. Its drug candidates, spevatamig and peluntamig, hold both orphan drug and Fast Track designations from the FDA. The company utilizes its proprietary technology platforms, PACbody, SPECpair, and ATACCbody, to advance novel biologics aimed at addressing significant unmet needs in immuno-oncology.